InterMune Inc. (ITMN)

[ghmm]

The ASCEND results are quite good. Here is what I wrote on another board.

At first glance this would be a triple and would seem superior to what we know about the BI drug to date. Meeting the survival end point (pooled with CAPACITY) which was predefined was a key. Also the 6 minute walk test showing significance is important as its used in other lung diseases for approval. A home run would have been meeting survival in ASCEND alone, it should be noted the company had PREVIOUSLY stated the trial was not powered to do so, nor was it a stated requirement for approval but pooled at least a trend would have been necessary.

For disclosure I am still long ITMN but had sold a descent portion of my holdings prior and I am long ITMN in my SI portfolio.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97801516